Aphasia

Summary

Aphasia (MONDO:0000598) is a disease and 239 clinical trials. Top therapeutic interventions include donepezil, levodopa, and memantine. A subtype of language disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• ClinVar variants: 1
• Clinical trials: 239

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	aphasia
Mondo ID	MONDO:0000598
MeSH	D001037
DOID	DOID:0060046
ICD-10-CM	R47.01
ICD-11	1167055901
UMLS	C0003537
MedGen	8159
Is cancer (heuristic)	no

Data availability: 1 ClinVar variant.

Disease family

This is a subtype of language disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › communication disorder › language disorder › aphasia

Related subtypes (5): stutter disorder, specific language impairment, expressive language disorder, mixed receptive-expressive language disorder, articulation disorder

Subtypes (1): nominal aphasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
267936	46;XY;t(12;14)(q15;q13)mat		Uncertain significance	criteria provided, single submitter

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Donepezil	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Escitalopram, Levodopa.

Clinical trials & evidence

Clinical trials

Clinical trials: 239.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	207
PHASE2	15
PHASE1	5
PHASE4	4
PHASE3	3
PHASE1/PHASE2	2
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00102869	PHASE4	COMPLETED	Dopaminergic Enhancement of Learning and Memory in Aphasia
NCT00196690	PHASE4	COMPLETED	Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial
NCT00196703	PHASE4	UNKNOWN	Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
NCT00640198	PHASE4	COMPLETED	Memantine and Intensive Speech-Language Therapy in Aphasia
NCT00822068	PHASE2/PHASE3	UNKNOWN	Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation
NCT00903266	PHASE3	COMPLETED	Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia
NCT01277575	PHASE3	TERMINATED	Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia
NCT04134416	PHASE3	COMPLETED	Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia
NCT03843463	PHASE2	RECRUITING	Escitalopram and Language Intervention for Subacute Aphasia
NCT05653440	PHASE2	RECRUITING	Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
NCT05653466	PHASE2	RECRUITING	Adaptive Trial Scheduling in Naming Treatment for Aphasia
NCT06842745	PHASE2	RECRUITING	Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
NCT06968663	PHASE2	RECRUITING	Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
NCT07036406	PHASE2	RECRUITING	Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)
NCT07397923	PHASE2	RECRUITING	Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia
NCT00567242	PHASE1/PHASE2	COMPLETED	Treating Intention In Aphasia: Neuroplastic Substrates
NCT00814697	PHASE2	COMPLETED	Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer’s Disease
NCT01300624	PHASE2	COMPLETED	Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia
NCT01686373	PHASE2	COMPLETED	Brain Stimulation and Aphasia Treatment
NCT01924702	PHASE2	UNKNOWN	Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)
NCT02249819	PHASE1/PHASE2	TERMINATED	Evaluating Anodal tDCS Preceding Aphasia Therapy
NCT02540109	PHASE2	COMPLETED	Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study
NCT03651700	PHASE2	COMPLETED	Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia
NCT04364854	PHASE2	COMPLETED	Speech Entrainment for Aphasia Recovery
NCT04937452	PHASE2	COMPLETED	Dopaminergic Therapy for Frontotemporal Dementia Patients
NCT00227461	PHASE1	UNKNOWN	Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
NCT00608582	PHASE1	COMPLETED	Transcranial Magnetic Stimulation to Improve Speech in Aphasia
NCT01623284	PHASE1	COMPLETED	PiB PET Scanning in Speech and Language Based Dementias
NCT01651884	PHASE1	COMPLETED	Effects of tDCS Versus HD-tDCS for Stroke Rehabilitation
NCT05847023	PHASE1	COMPLETED	Proof-of-concept Study of LUNA Intervention in Aphasia
NCT06511752	EARLY_PHASE1	RECRUITING	Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
NCT04816799	EARLY_PHASE1	UNKNOWN	Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia
NCT03929432	Not specified	RECRUITING	Treatment Outcomes With tDCS in Post-Stroke Aphasia
NCT03930121	Not specified	ACTIVE_NOT_RECRUITING	Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia
NCT04142866	Not specified	RECRUITING	Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
NCT04215952	Not specified	ACTIVE_NOT_RECRUITING	Semantic Feature Analysis Treatment for Aphasia
NCT04375722	Not specified	RECRUITING	Transcranial Alternating Current Stimulation (tACS) in Aphasia
NCT04432883	Not specified	RECRUITING	Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.
NCT04604444	Not specified	RECRUITING	Changes in Neuroplasticity Following Intensive Rehabilitation of Aphasia and/or Apraxia of Speech
NCT04682223	Not specified	RECRUITING	Telerehabilitation for Aphasia (TERRA)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DONEPEZIL	4	2
LEVODOPA	4	2
MEMANTINE	4	2
GALANTAMINE	4	1
ROTIGOTINE	4	1
BENSERAZIDE	3	1
CHEMBL351042	0	1
CHEMBL104383	0	1
CHEMBL1385	0	1
CHEMBL3764305	0	1
CHEMBL46909	0	1